Search

Displaying results 811 - 820 of 4600 in total
  1. Drug

    Paroxetine

    go.drugbank.com/drugs/DB00715
    ApprovedInvestigational

    [T653] It was approved by the FDA in the early 1990s and marketed by SmithKline Beecham.

  2. Drug

    Tropicamide

    go.drugbank.com/drugs/DB00809
    Approved

    [A229958] It is also used in combination with [hydroxyamphetamine] for the same indication.

  3. Drug

    Borneol

    go.drugbank.com/drugs/DB11288
    ApprovedInvestigational

    Mixtures: Menthol Overnight Pain Relief Gel-Patch
  4. Drug

    Elacestrant

    go.drugbank.com/drugs/DB06374
    ApprovedInvestigational

    [A256838,L44918] In January 2023, it was approved by the FDA for the treatment of ER-positive, HER2-negative, ESR1-mutated advanced or metastatic breast cancer.

  5. Drug

    Spesolimab

    go.drugbank.com/drugs/DB15626
    ApprovedInvestigational

    It is a humanized monoclonal immunoglobulin G1 antibody that was produced in Chinese hamster ovary (CHO) cells by recombinant DNA technology. … The biosimilar of the drug, spesolimab-sbzo, was first approved by the FDA in September 2022 to treat generalized pustular psoriasis flares.

  6. Drug

    Pentastarch

    go.drugbank.com/drugs/DB09111
    ApprovedWithdrawn

    It is sold under the name Pentaspan by Bristol-Myers Squibb and is used for fluid resuscitation. … Pentastarch is characterized by presenting five hydroxyethyl groups, which signifies an approximate 50% hydroxyethylation.

  7. Drug

    Diclofenamide

    go.drugbank.com/drugs/DB01144
    Approved

    A carbonic anhydrase inhibitor that is used in the treatment of glaucoma.

  8. Drug

    Benralizumab

    go.drugbank.com/drugs/DB12023
    ApprovedInvestigational

    [A31293] Benralizumab was FDA approved on November 14, 2017, and was developed by MedImmune, AstraZeneca's global biologic research and development arm.[L1019]

  9. Drug

    Sarafloxacin

    go.drugbank.com/drugs/DB11491
    ApprovedVet approvedWithdrawn

    Sarafloxacin is a quinolone antibiotic drug, which was discontinued by its manufacturer, Abbott Laboratories, before receiving approval for use in the US or Canada.

  10. Drug

    Rolapitant

    go.drugbank.com/drugs/DB09291
    ApprovedInvestigational

    By blocking Substance P from interacting with NK-1 receptors in the gut and the central nervous system, rolapitant prevents late-phase CINV. … Delayed-phase CINV typically occurs >24 hours after chemotherapy treatment and is principally mediated by Neurokinin-1 and its ligand Substance P, which is released in the gut following chemotherapy administration